HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says

This article was originally published in The Tan Sheet

Executive Summary

Use of a "black box" warning on OTC acetaminophen labeling would be an inappropriate means for alerting consumers about potential liver damage, two consultants to FDA's Nonprescription Drugs Advisory Committee said Sept. 19

Related Content

McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol
Sen. Grassley Questions FDA’s Response To Acetaminophen Concerns
Tylenol Ads Touting Superior Safety To NSAIDs May Mislead Consumers – NAD
FDA, NCL Launch “Take With Care” OTC Analgesic Safety Campaign
Acetaminophen research
OTC Analgesic Label Warnings Should Extend To Advertising, Committee Says
Acetaminophen Special Populations Toxicity Data Lacking, NDAC Says
Voluntary Acetaminophen Labeling Revisions Include Overdose Warning
Voluntary Acetaminophen Labeling Revisions Include Overdose Warning
Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts